PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Hippocratic AI Secures $53M to Develop Safety-Focused GenAI for Healthcare

What You Should Know: – Hippocratic AI, a company developing a safety-focused Large Language Model (LLM) for healthcare raises $53M in Series A funding, bringing

March 19, 2024

Vitalli Bio formed to focus on immunological disorders

Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is

April 28, 2023

TAVR for aortic regurgitation: Moving beyond “off-label” use

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Transcatheter aortic valve replacement (TAVR) is currently a widely used option for patients with

July 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.